50
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Multidrug resistance (MDR) is one of the major obstacles in cancer chemotherapy. Our previous study has shown that icariin could reverse MDR in MG-63 doxorubicin-resistant (MG-63/DOX) cells. It is reported that icariin is usually metabolized to icaris-ide II and icaritin. Herein, we investigated the effects of icariin, icariside II, and icaritin (ICT) on reversing MDR in MG-63/DOX cells. Among these compounds, ICT exhibited strongest effect and showed no obvious cytotoxicity effect on both MG-63 and MG-63/DOX cells ranging from 1 to 10 μmol·L −1. Furthermore, ICT increased accumulation of rhodamine 123 and 6-carboxyfluorescein diacetate and enhanced DOX-induced apoptosis in MG-63/DOX cells in a dose-dependent manner. Further studies demonstrated that ICT decreased the mRNA and protein levels of multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 1 (MRP1). We also verified that blockade of STAT3 phosphorylation was involved in the reversal effect of multidrug resistance in MG-63/DOX cells. Taken together, these results indicated that ICT may be a potential candidate in chemotherapy for osteosarcoma.

          Author and article information

          Journal
          CJNM
          Chinese Journal of Natural Medicines
          Elsevier
          1875-5364
          20 January 2018
          : 16
          : 1
          : 20-28
          Affiliations
          [1] 1State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
          Author notes
          *Corresponding authors: KONG Ling-Yi, Tel/Fax: 86-25-83271405, E-mails: cpu_lykong@ 123456126.com ; YANG Lei, dorothy19802003@ 123456gmail.com

          ΔThese authors contributed equally to this work.

          These authors have no conflict of interest to declare.

          Article
          S1875-5364(18)30026-8
          10.1016/S1875-5364(18)30026-8
          29425587
          363ba2f9-2927-4e52-887c-a17fb33af6d8
          Copyright © 2018 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          History
          : 25 May 2017
          Funding
          Funded by: National Natural Science Foundation of China
          Award ID: 81673554
          Award ID: 81503211
          Funded by: Natural Science Foundation of Jiangsu Province
          Award ID: BK20160763
          This work was supported by the National Natural Science Foundation of China (Nos. 81673554 and 81503211), Natural Science Foundation of Jiangsu Province (No. BK20160763), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) and the Program for Changjiang Scholars and Innovative Research Team in University (No. IRT_15R63).

          Medicine,Pharmaceutical chemistry,Pharmacology & Pharmaceutical medicine,Complementary & Alternative medicine
          Osteosarcoma,MDR1,MRP1,Icaritin,Multidrug resistance

          Comments

          Comment on this article